08:00 Mon 15 May 2017
Redx Pharma plc - Preclinical efficacy data presented on RXC005
AIM: REDX
Abstract #219
Poster #210
("Redx" or "the Company")
Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th
The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.
RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members. RXC005 demonstrated significant efficacy in ABC-DLBCL xenograft mouse models such as TMD8 and OCI-Ly10 cell lines.
The poster can be found on the Company's website www.redxpharma.com
Dr
Dr
For further information, please contact:
|
|
|
T: +44 1625 469 900 |
Karl Hård, Head of
|
T: +44 7491 651 406 |
|
T: +44 20 7894 7000 |
|
|
|
|
|
T: +44 20 3705 9330 |
Claes Spång/ |
|
|
T: +44 20 3709 5700 |
|
|
About
Company website: www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE